BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19165202)

  • 1. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
    Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H
    Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma.
    Charlet J; Szemes M; Malik KT; Brown KW
    Mol Carcinog; 2014 May; 53(5):413-20. PubMed ID: 23280764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.
    Haruta M; Kamijo T; Nakagawara A; Kaneko Y
    Cancer Lett; 2014 Jun; 348(1-2):167-76. PubMed ID: 24680815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma.
    Sugawara W; Haruta M; Sasaki F; Watanabe N; Tsunematsu Y; Kikuta A; Kaneko Y
    Pediatr Blood Cancer; 2007 Sep; 49(3):240-9. PubMed ID: 16937357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
    Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
    Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RASSF1A promoter hypermethylation as a prognostic marker for hepatocellular carcinoma.
    Saelee P; Wongkham S; Chariyalertsak S; Petmitr S; Chuensumran U
    Asian Pac J Cancer Prev; 2010; 11(6):1677-81. PubMed ID: 21338215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    S SK; Swamy SN; Premalatha CS; Pallavi VR; Gawari R
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):3001-3005. PubMed ID: 31653147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
    Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
    J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
    Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
    Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
    Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB
    World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of LINE-1 hypomethylation and RASSF1A promoter hypermethylation in serum DNA is a non-invasion prognostic biomarker for early recurrence of hepatocellular carcinoma after curative resection.
    Liu ZJ; Huang Y; Wei L; He JY; Liu QY; Yu XQ; Li ZL; Zhang J; Li B; Sun CJ; Liang WB; Sun AM; Qin Y
    Neoplasma; 2017; 64(5):795-802. PubMed ID: 28592132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients.
    Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y
    Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer.
    Wang Y; Yu Z; Wang T; Zhang J; Hong L; Chen L
    Lung Cancer; 2007 May; 56(2):289-94. PubMed ID: 17267069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.
    Lázcoz P; Muñoz J; Nistal M; Pestaña A; Encío I; Castresana JS
    BMC Cancer; 2006 Oct; 6():254. PubMed ID: 17064406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
    Wang J; Wang B; Chen X; Bi J
    Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.